These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1087 related articles for article (PubMed ID: 29856033)

  • 1. Translating Antisense Technology into a Treatment for Huntington's Disease.
    Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
    Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
    Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
    Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
    Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease.
    Caron NS; Aly AE; Findlay Black H; Martin DDO; Schmidt ME; Ko S; Anderson C; Harvey EM; Casal LL; Anderson LM; Rahavi SMR; Reid GSD; Oda MN; Stanimirovic D; Abulrob A; McBride JL; Leavitt BR; Hayden MR
    J Control Release; 2024 Mar; 367():27-44. PubMed ID: 38215984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
    Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
    Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleic Acid Therapeutics in Huntington's Disease.
    Singh K; Roy I
    Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.
    Gagnon KT; Pendergraff HM; Deleavey GF; Swayze EE; Potier P; Randolph J; Roesch EB; Chattopadhyaya J; Damha MJ; Bennett CF; Montaillier C; Lemaitre M; Corey DR
    Biochemistry; 2010 Nov; 49(47):10166-78. PubMed ID: 21028906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies.
    Dash D; Mestre TA
    Neurotherapeutics; 2020 Oct; 17(4):1645-1659. PubMed ID: 32705582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.
    Miniarikova J; Evers MM; Konstantinova P
    Mol Ther; 2018 Apr; 26(4):947-962. PubMed ID: 29503201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic.
    Rook ME; Southwell AL
    BioDrugs; 2022 Mar; 36(2):105-119. PubMed ID: 35254632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic strategies for Huntington's disease.
    Estevez-Fraga C; Flower MD; Tabrizi SJ
    Curr Opin Neurol; 2020 Aug; 33(4):508-518. PubMed ID: 32657893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.
    Carroll JB; Warby SC; Southwell AL; Doty CN; Greenlee S; Skotte N; Hung G; Bennett CF; Freier SM; Hayden MR
    Mol Ther; 2011 Dec; 19(12):2178-85. PubMed ID: 21971427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Antisense Oligonucleotide Gapmers for the Treatment of Huntington's Disease.
    Aslesh T; Yokota T
    Methods Mol Biol; 2020; 2176():57-67. PubMed ID: 32865782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Huntington's Disease: Latest Frontiers in Therapeutics.
    Saade J; Mestre TA
    Curr Neurol Neurosci Rep; 2024 Aug; 24(8):255-264. PubMed ID: 38861215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of mutant and total huntingtin expression in Huntington's disease murine models.
    Fodale V; Pintauro R; Daldin M; Altobelli R; Spiezia MC; Bisbocci M; Macdonald D; Bresciani A
    Sci Rep; 2020 Dec; 10(1):22137. PubMed ID: 33335120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides.
    Southwell AL; Skotte NH; Kordasiewicz HB; Østergaard ME; Watt AT; Carroll JB; Doty CN; Villanueva EB; Petoukhov E; Vaid K; Xie Y; Freier SM; Swayze EE; Seth PP; Bennett CF; Hayden MR
    Mol Ther; 2014 Dec; 22(12):2093-2106. PubMed ID: 25101598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease.
    Southwell AL; Kordasiewicz HB; Langbehn D; Skotte NH; Parsons MP; Villanueva EB; Caron NS; Østergaard ME; Anderson LM; Xie Y; Cengio LD; Findlay-Black H; Doty CN; Fitsimmons B; Swayze EE; Seth PP; Raymond LA; Frank Bennett C; Hayden MR
    Sci Transl Med; 2018 Oct; 10(461):. PubMed ID: 30282695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
    Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
    J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities.
    Tabrizi SJ; Estevez-Fraga C; van Roon-Mom WMC; Flower MD; Scahill RI; Wild EJ; Muñoz-Sanjuan I; Sampaio C; Rosser AE; Leavitt BR
    Lancet Neurol; 2022 Jul; 21(7):645-658. PubMed ID: 35716694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.